Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study.
Mata Marín JA, Velasco-Penagos JC, Mauss S, Rodriguez-Evaristo MS, Pérez-Barragán E, Villa-Platas J, Barragán-Huerta L, Gaytán-Martínez JE. Mata Marín JA, et al. Among authors: mauss s. Int J STD AIDS. 2024 Jan;35(1):33-38. doi: 10.1177/09564624231196605. Epub 2023 Sep 20. Int J STD AIDS. 2024. PMID: 37729763
Risk factors for mortality and clinical presentation of monkeypox.
Triana-González S, Román-López C, Mauss S, Cano-Díaz AL, Mata-Marín JA, Pérez-Barragán E, Pompa-Mera E, Gaytán-Martínez JE. Triana-González S, et al. Among authors: mauss s. AIDS. 2023 Nov 1;37(13):1979-1985. doi: 10.1097/QAD.0000000000003623. Epub 2023 Jun 8. AIDS. 2023. PMID: 37294338
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up.
Cano Díaz AL, Triana González S, Salinas Velázquez GE, Mata Marín JA, Gaytán Martínez JE, Mauss S. Cano Díaz AL, et al. Among authors: mauss s. Int J STD AIDS. 2025 Jan;36(1):36-41. doi: 10.1177/09564624241287886. Epub 2024 Sep 27. Int J STD AIDS. 2025. PMID: 39331786
Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
Stephan C, Spinner CD, Rieke A, Christensen S, Mauss S, Schreiber S, Albuquerque B, Heinzkill M, Ramroth H, Stellbrink HJ. Stephan C, et al. Among authors: mauss s. HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728. Online ahead of print. HIV Med. 2024. PMID: 39476488
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021.
Meyer ED, Dudareva S, Kollan C, Mauss S, Wedemeyer H, Schmidt D, Zimmermann R. Meyer ED, et al. Among authors: mauss s. Front Public Health. 2023 May 30;11:1149694. doi: 10.3389/fpubh.2023.1149694. eCollection 2023. Front Public Health. 2023. PMID: 37325322 Free PMC article.
254 results